Given their essential roles in genome maintenance and cancer adaptation, APE1 and APE2 have emerged as promising therapeutic targets, with APE1 inhibitors already developed in the past two decades and APE2 representing a novel frontier for precision oncology. This evidence concerns the gene APEX1 and cancer.